Vaxart Inc. (NASDAQ: VXRT) reviewed 10-13-2020
Market Cap: 737.4 Million (USD) Share Price: $7.67 (USD)
Shares outstanding: 96,140,166 at 30 Jun 2020
Cash & cash equivalents: $ 44.4 M (USD) at 30 Jun 2020
Debt: Nil
Insiders: Low, 1.2% Institutional: 36 hold ~37% of float
Website: vaxart.com
Investor Presentations: https://investors.vaxart.com/static-files/64808110-9390-4735-8076-392f35605b82
CEO: Andrei Floroiu HQs: Boston, Mass, USA
The company develops vaccines that can be delivered via tablet form versus traditional injections
R&D pipeline includes four prophylactic vaccines in addition to seeking licenses, to address these viruses:
- COVID-19 – on 13 Oct 2020 announced the 1st dosing of a human subject in Phase 1 Trial (oral tablet vaccine)
- Influenza – Phase 1
- Novovirus – Phase 1
- Respiratory Syncytial Virus (RSV) – Pre-clinical
- Also developing human papillomavirus (HPV) vaccine
Unprofitable: Q2 2020 Revenues of $523,000 (USD) vs operating expenses of $9 Million (USD)
Bottom line:
- We have a position
- Their oral vaccine delivery system will be favored over needles that inject fluids into your body
- In mass production, their technology will be far less costly than the competition
- Presently, this technology is in phase 1 clinical trial whereas the competition is mostly in phases 2 & 3. But if Vaxaer is successful, they could receive ~$400 million in OWS funding